{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:54:59Z","timestamp":1789440899730,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The efficacy of loncastuximab tesirine (lonca) following chimeric antigen receptor T-cell therapy (CAR-T) progression\/failure is unknown. Hence, we sought to examine real-world use and outcomes of lonca following CAR-T in patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) in the USA. In this retrospective study, we included adults (age\u2009\u2265\u200918 years) with R\/R DLBCL who received lonca monotherapy as third- (3\u2009L) or fourth line (4\u2009L) treatment after progressing on second line (2\u2009L) or 3\u2009L CAR-T, respectively. Post-CAR-T lonca outcomes included response rates (overall response rate [ORR] and complete response [CR] rate), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). A total of 118 patients were included in the analysis with 95 receiving lonca following 2\u2009L CAR-T (median age:66 years; 61% male) and 23 following 3\u2009L CAR-T (median age:57 years; 43% male). Patients with 2\u2009L CAR-T\/3\u2009L lonca had an ORR of 73% (CR rate of 34%). With a median follow-up of 8.5 months following lonca initiation, median DOR, PFS, and OS were not reached. The DOR, PFS, and OS at 12 months were 68%, 77%, and 84%, respectively. Patients with 3\u2009L CAR-T\/4\u2009L lonca had an ORR of 78% (CR rate of 17%). With a median follow-up of 13 months following lonca initiation, the median DOR and PFS were 7.6 and 12.0 months, while median OS was not reached. OS at 12 months was 95%. In this study, we found that lonca monotherapy was an effective treatment option in R\/R DLBCL in 3\u2009L and 4\u2009L settings including those who were resistant to or progressed after CAR-T.<\/jats:p>","DOI":"10.1038\/s41408-024-01195-4","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T03:46:08Z","timestamp":1732765568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Lucero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mirams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolenta","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Amet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Milligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"1195_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"1195_CR2","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.24086","volume":"90","author":"M Al-Hamadani","year":"2015","unstructured":"Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90:790\u20135.","journal-title":"Am J Hematol"},{"key":"1195_CR3","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","volume":"32","author":"MJ Maurer","year":"2014","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Jais JP, Witzig TE, Haioun C, Thompson CA, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32:1066\u201373.","journal-title":"J Clin Oncol"},{"key":"1195_CR4","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.","journal-title":"J Clin Oncol"},{"key":"1195_CR5","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800\u20138.","journal-title":"Blood"},{"key":"1195_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221087511","volume":"13","author":"F Furqan","year":"2022","unstructured":"Furqan F, Hamadani M. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data. Ther Adv Hematol. 2022;13:20406207221087511.","journal-title":"Ther Adv Hematol"},{"key":"1195_CR7","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184\u201390.","journal-title":"J Clin Oncol"},{"key":"1195_CR8","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.jtct.2023.06.012","volume":"29","author":"N Epperla","year":"2023","unstructured":"Epperla N, Kumar A, Abutalib SA, Awan FT, Chen YB, Gopal AK, et al. ASTCT clinical practice recommendations for transplantation and cellular therapies in diffuse large B cell lymphoma. Transpl Cell Ther. 2023;29:548\u201355.","journal-title":"Transpl Cell Ther"},{"key":"1195_CR9","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32:3490\u20136.","journal-title":"J Clin Oncol"},{"key":"1195_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-015-0465-x","volume":"17","author":"OB Lahoud","year":"2015","unstructured":"Lahoud OB, Sauter CS, Hamlin PA, Dahi PB. High-dose chemotherapy and autologous stem cell transplant in older patients with lymphoma. Curr Oncol Rep. 2015;17:42.","journal-title":"Curr Oncol Rep"},{"key":"1195_CR11","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1182\/bloodadvances.2019000102","volume":"3","author":"N Epperla","year":"2019","unstructured":"Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini NY, et al. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood Adv. 2019;3:1661\u20139.","journal-title":"Blood Adv"},{"key":"1195_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/hon.3153","volume":"41","author":"AP Boardman","year":"2023","unstructured":"Boardman AP, Salles G. CAR T-cell therapy in large B cell lymphoma. Hematol Oncol. 2023;41:112\u20138.","journal-title":"Hematol Oncol"},{"key":"1195_CR13","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"1195_CR14","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","volume":"25","author":"N Bouchkouj","year":"2019","unstructured":"Bouchkouj N, Kasamon YL, de Claro RA, George B, Lin X, Lee S, et al. FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Clin Cancer Res. 2019;25:1702\u20138.","journal-title":"Clin Cancer Res"},{"key":"1195_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"1195_CR16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839\u201352.","journal-title":"Lancet"},{"key":"1195_CR17","unstructured":"Administration FaD. FDA approves lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma Silver Spring, MD: U.S. Department of Health and Human Services; 2021. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-large-b-cell-lymphoma."},{"key":"1195_CR18","unstructured":"Administration FaD. FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma Silver Spring, MD: U.S. Department of Health and Human Services; 2018. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-adults-relapsed-or-refractory-large-b-cell-lymphoma."},{"key":"1195_CR19","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640\u201354.","journal-title":"N Engl J Med"},{"key":"1195_CR20","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1158\/1078-0432.CCR-23-0568","volume":"29","author":"P Sharma","year":"2023","unstructured":"Sharma P, Kasamon YL, Lin X, Xu Z, Theoret MR, Purohit-Sheth T. FDA approval summary: axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma. Clin Cancer Res. 2023;29:4331\u20137.","journal-title":"Clin Cancer Res"},{"key":"1195_CR21","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","volume":"23","author":"A Sehgal","year":"2022","unstructured":"Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022;23:1066\u201377.","journal-title":"Lancet Oncol"},{"key":"1195_CR22","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399:2294\u2013308.","journal-title":"Lancet"},{"key":"1195_CR23","unstructured":"Administration FaD. FDA approves lisocabtagene maraleucel for second-line treatment of large B-cell lymphoma Silver Spring, MD: U.S. Department of Health and Human Services; 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lisocabtagene-maraleucel-second-line-treatment-large-b-cell-lymphoma."},{"key":"1195_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000185","volume":"3","author":"G Hopfinger","year":"2019","unstructured":"Hopfinger G, J\u00e4ger U, Worel N. CAR-T cell therapy in diffuse large B cell lymphoma: hype and hope. Hemasphere. 2019;3:e185.","journal-title":"Hemasphere"},{"key":"1195_CR25","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1182\/bloodadvances.2020002118","volume":"4","author":"D Sermer","year":"2020","unstructured":"Sermer D, Batlevi C, Palomba ML, Shah G, Lin RJ, Perales MA, et al. Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Adv. 2020;4:4669\u201378.","journal-title":"Blood Adv"},{"key":"1195_CR26","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1631\/jzus.B2200256","volume":"23","author":"T Gu","year":"2022","unstructured":"Gu T, Zhu M, Huang H, Hu Y. Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches. J Zhejiang Univ Sci B. 2022;23:793\u2013811.","journal-title":"J Zhejiang Univ Sci B"},{"key":"1195_CR27","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1182\/blood.2022016945","volume":"140","author":"R Di Blasi","year":"2022","unstructured":"Di Blasi R, Le Gouill S, Bachy E, Cartron G, Beauvais D, Le Bras F, et al. Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. Blood. 2022;140:2584\u201393.","journal-title":"Blood"},{"key":"1195_CR28","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22:790\u2013800.","journal-title":"Lancet Oncol"},{"key":"1195_CR29","doi-asserted-by":"publisher","first-page":"e1006","DOI":"10.1016\/S2352-3026(23)00307-1","volume":"10","author":"P Dreger","year":"2023","unstructured":"Dreger P, Corradini P, Gribben JG, Glass B, Jerkeman M, Kersten MJ, et al. CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach. Lancet Haematol. 2023;10:e1006\u2013e15.","journal-title":"Lancet Haematol"},{"key":"1195_CR30","first-page":"1184","volume":"109","author":"PF Caimi","year":"2024","unstructured":"Caimi PF, Ai WZ, Alderuccio JP, et al. Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica. 2024;109:1184\u20131193.","journal-title":"Haematologica"},{"key":"1195_CR31","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"1195_CR32","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1182\/blood-2023-174257","volume":"142","author":"E Ayers","year":"2023","unstructured":"Ayers E, Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, et al. Loncastuximab in high-risk and heavily-pretreated relapsed\/refractory diffuse large B-cell lymphoma: a real world analysis from 21 US centers. Blood. 2023;142:312.","journal-title":"Blood"},{"key":"1195_CR33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1182\/blood-2023-174497","volume":"142","author":"LJ Nastoupil","year":"2023","unstructured":"Nastoupil LJ, Andersen CR, Ayers A, Wang Y, Habermann TM, Chihara D, et al. Effectiveness of chemo-immunotherapy (CIT) and novel therapies in second or later line of therapy (2L+) for patients with relapsed\/refractory (R\/R) aggressive large B-cell lymphoma (LBCL). Blood. 2023;142:309.","journal-title":"Blood"},{"key":"1195_CR34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41409-023-02148-4","volume":"59","author":"M Iqbal","year":"2024","unstructured":"Iqbal M, Jagadeesh D, Chavez J, Khurana A, Rosenthal A, Craver E, et al. Efficacy of CD19 directed therapies in patients with relapsed or refractory large B-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy. Bone Marrow Transplant. 2024;59:211\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"1195_CR35","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1016\/j.clml.2021.11.005","volume":"22","author":"PF Caimi","year":"2022","unstructured":"Caimi PF, Ardeshna KM, Reid E, Ai W, Lunning M, Zain J, et al. The AntiCD19 antibody drug immunoconjugate loncastuximab achieves responses in DLBCL relapsing after AntiCD19 CAR-T cell therapy. Clin Lymphoma Myeloma Leuk. 2022;22:e335\u2013e9.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1195_CR36","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1182\/bloodadvances.2022008240","volume":"7","author":"J Zurko","year":"2023","unstructured":"Zurko J, Nizamuddin I, Epperla N, David K, Cohen JB, Moyo TK, et al. Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL. Blood Adv. 2023;7:2657\u201369.","journal-title":"Blood Adv"},{"key":"1195_CR37","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41409-023-02176-0","volume":"59","author":"S El Warrak","year":"2024","unstructured":"El Warrak S, Kharfan-Dabaja MA, Iqbal M, Hamadani M, Chavez J, Mohty R, et al. Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy. Bone Marrow Transplant. 2024;59:162\u2013170.","journal-title":"Bone Marrow Transplant"},{"key":"1195_CR38","doi-asserted-by":"publisher","first-page":"101140","DOI":"10.1016\/j.blre.2023.101140","volume":"63","author":"TR Brooks","year":"2024","unstructured":"Brooks TR, Caimi PF. A paradox of choice: Sequencing therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Rev. 2024;63:101140. https:\/\/doi.org\/10.1016\/j.blre.2023.101140.","journal-title":"Blood Rev."},{"key":"1195_CR39","doi-asserted-by":"publisher","first-page":"342.e1","DOI":"10.1016\/j.jtct.2022.02.021","volume":"28","author":"AM Sigmund","year":"2022","unstructured":"Sigmund AM, Denlinger N, Huang Y, Bond D, Voorhees T, Bajwa A, et al. Assessment of salvage regimens post-chimeric antigen receptor T cell therapy for patients with diffuse large B cell lymphoma. Transpl Cell Ther. 2022;28:342.e1\u2013e5.","journal-title":"Transpl Cell Ther"},{"key":"1195_CR40","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","volume":"37","author":"A Alarcon Tomas","year":"2023","unstructured":"Alarcon Tomas A, Fein JA, Fried S, Flynn JR, Devlin SM, Fingrut WB, et al. Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma. Leukemia. 2023;37:154\u201363.","journal-title":"Leukemia"},{"key":"1195_CR41","first-page":"1832","volume":"137","author":"JY Spiegel","year":"2021","unstructured":"Spiegel JY, Dahiya S, Jain MD, Tamaresis J, Nastoupil LJ, Jacobs MT, et al. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood. 2021;137:1832\u20135.","journal-title":"Blood"},{"key":"1195_CR42","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1182\/bloodadvances.2023010016","volume":"7","author":"A Major","year":"2023","unstructured":"Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, et al. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023;7:4528\u201338.","journal-title":"Blood Adv"},{"key":"1195_CR43","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00277-023-05088-7","volume":"102","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Ai S, Cong M, Jin M, Ma X, Huang H. Venetoclax-based combination therapy in R\/R DLBCL patients with failure of CAR-T therapy. Ann Hematol. 2023;102:597\u2013601.","journal-title":"Ann Hematol"},{"key":"1195_CR44","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1097\/01.HS9.0000848648.00591.47","volume":"6","author":"P Derigs","year":"2022","unstructured":"Derigs P, Bethge W, Holtick U, von Tresckow B, Ayuk F, Penack O, et al. P1448: long-term survivors after failure of CAR-T cell therapy for R\/R large B-cell lymphoma (LBCL): a GLA\/DRST study. HemaSphere. 2022;6:1331\u20132.","journal-title":"HemaSphere"},{"key":"1195_CR45","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1097\/01.HS9.0000847588.33528.e3","volume":"6","author":"C Flores Avile","year":"2022","unstructured":"Flores Avile C, Liao L, Wilson L, Lau A, Chen L. P1181: real-world characteristics and clinical outcomes in relapse\/refractory diffuse large B-cell lymphoma post CAR-T failure. HemaSphere. 2022;6:1067\u20138.","journal-title":"HemaSphere"},{"key":"1195_CR46","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.3324\/haematol.2023.282804","volume":"108","author":"HS Ababneh","year":"2023","unstructured":"Ababneh HS, Ng AK, Frigault MJ, Abramson JS, Johnson PC, Jacobson CA, et al. Salvage radiotherapy in relapsed\/refractory large B-cell lymphoma after failure of CAR T-cell therapy. Haematologica. 2023;108:2972\u201381.","journal-title":"Haematologica"},{"key":"1195_CR47","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s40265-023-01930-4","volume":"83","author":"JE Frampton","year":"2023","unstructured":"Frampton JE. Epcoritamab: first approval. Drugs. 2023;83:1331\u201340.","journal-title":"Drugs"},{"key":"1195_CR48","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol. 2023;41:2238\u201347.","journal-title":"J Clin Oncol"},{"key":"1195_CR49","unstructured":"Administration FaD. FDA grants accelerated approval to glofitamab-gxbm for selected relapsed or refractory large B-cell lymphomas Silver Spring, MD: U.S. Department of Health and Human Services; 2023. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-glofitamab-gxbm-selected-relapsed-or-refractory-large-b-cell."},{"key":"1195_CR50","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387:2220\u201331.","journal-title":"N Engl J Med"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01195-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01195-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01195-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T05:28:27Z","timestamp":1732771707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01195-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1195"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01195-4","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"17 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NE provides consultancy for ADC Therapeutics. He is a member of the Speakers Bureau for Beigene, and Genentech. He also received research funding from Beigene, Lilly, and Incyte. TB, LM, JC, MA and GM are employees of Adelphi Real World, who received funding from ADC Therapeutics for this work. ML and LC were employees of ADC Therapeutics at the time of the study and currently own stock in the company.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}